Upload
jirapornspp
View
1.277
Download
0
Embed Size (px)
DESCRIPTION
Citation preview
Nuclear Oncologygyfor medical students
Jiraporn Sriprapaporn,M.D.Di N l di iDiv Nuclear medicine
Siriraj Hospital Mahidol University Bangkok
N l O lNuclear Oncology
Conventional Tumor ImagingImaging
WB+ PlanarSPECTSPECTSPECT/CT
Onco PET (Positron Emission Tomography)
PETPET/CT
J Sriprapaporn
Objectives of Tumor Imaging
DiagnosisgStagingGuiding for biopsyFollow up & monitoringFollow-up & monitoring treatmentDetect tumor recurrence
J Sriprapaporn
Nuclear Oncology
Functional Med LN
SensitiveWhole body evaluationWhole-body evaluationSpecific-some tumors
ADR
RP LNp
J Sriprapaporn
Conventional Tumor Imaging
Ga 67 citrate I 131 (DTC)Ga-67 citrateTl-201T 99 MIBI
I-131 (DTC)I-131 MIBG (neural crest tumors)Tc-99m MIBI
Tc-99m Tetrofosmin
crest tumors)Receptor imaging eg somatostatineg. somatostatin Radiolabelled MoAb imaging
J Sriprapaporn
imaging
G lli 67Fever of unknown origin
(FUO)Gallium-67 (FUO)
Nonspecific for infection-inflammation & tumorsMechanism : bind to iron transport proteins egMechanism : bind to iron transport proteins eg. transferrin, lactoferrinE ti kid & l b lExcretion: kidneys & large bowelDose :5-10 mCi IV.Scan at 24-72 hr. pi.Tumors : Lymphoma (Hodgkin's lymphoma)Tumors : Lymphoma (Hodgkin s lymphoma),Bronchogenic carcinoma, Malignant melanoma, Hepatoma
J Sriprapaporn
Hepatoma
Objectives of Ga-67 Imaging in lymphoma
StagingStagingFollow-up & monitoringFollow up & monitoring treatmentDetect tumor recurrence
J Sriprapaporn
G lli 67 & L hGallium-67 & Lymphoma
Right paratracheal lymphadenopathyRight paratracheal lymphadenopathy
Planar Images SPECT ImagesJ Sriprapaporn
Planar Images SPECT Images
T 99 MIBI & Tl 201Tc-99m MIBI & Tl-201
Nonspecific tumor imagingp g gCan be applied in several types of ttumorsRapid information-imaging at 10-Rapid information imaging at 1020 min. pi.Uptake in viable tumor but not in scarred tissue
J Sriprapaporn
scarred tissue
Objectives of Tumor Imaging
Localize site for biopsyDetermine grade of malignancy Evaluate the response of preoperativeEvaluate the response of preoperative CMT or RTDetermine residual tumor &/or local recurrencerecurrenceDifferentiate post-therapy tissue necrosis o fib o i f om lo l e en e
J Sriprapaporn or fibrosis from local recurrence
I di iIndications
Brain tumorsBronchogenic carcinomaThyroid carcinomaThyroid carcinomaParathyroid adenomaB & ft tiBone & soft tissue sarcomaBreast cancerLymphoma : Head & neck cancers
J Sriprapaporn
Head & neck cancers
Bone Tumor PO. with Recurrence
Tc-99m MDP Tl-201
J Sriprapaporn
P h id AdParathyroid Adenoma
T 99 T 99 MIBITc-99m Tc-99m MIBI
J Sriprapaporn
I 131 MIBG SI-131 MIBG Scan
I-131 MetaiodobenzylguanidineN d li lNoradrenaline analogLocalizes in adrenergic tissues, catecholamine-producing tumors & theirmetastasesFirst synthesized by Wieland et al. in 1979Patient Preparation:Patient Preparation:
Withdrawal of drugs interfering MIBG uptakeLugol’s solution to block thyroid uptake of free
J Sriprapaporn
Lugol s solution to block thyroid uptake of free iodide
I 131 MIBG A id TI-131 MIBG-Avid Tumors
Pheochromocytoma/ eoc o ocyto a/ParagangliomaNeuroblastomaM d ll th id iMedullary thyroid carcinoma (MTC)(MTC)Carcinoid tumor
J Sriprapaporn
Bone Scan in Neuroblastoma20-2-44 (PreRx) 4-6-44 (PostRx)
3 yo girl
20 2 44 (PreRx) 4 6 44 (PostRx)
3 yo girlNBM stage IV with multiple bone metastases 2-44
Pre & post CMT 4 courses (induction)(induction)
J Sriprapaporn
I-131 MIBG in NeuroblastomaI-131 MIBG in Neuroblastoma
3 i l NBM t IV ith lti l b t 2 44
ANT POST
J Sriprapaporn
3 yo girl, NBM stage IV with multiple bone metas 2-44Pretreatment staging
I-131 MIBG in NeuroblastomaI-131 MIBG in Neuroblastoma
Girl, 3 yo.Neuroblastoma stage IV with multiple bone metastases 2-44Post 4 courses of CMT (induction)
ANT POST ANT POST
( )F/U after Rx
J Sriprapaporn 28-2-44 (PreRx) 6-6-44 (PostRx)
J Sriprapaporn J Sriprapaporn 2011
Wh i PET?What is PET?
PET =Positron Emission TomographyTomographyPET emitters emit positron from theirpositron from their nucleiPositron then reacts withPositron then reacts with electron annihilation
2 gamma photons2 gamma photons, 511 keV moving in opposite direction
J Sriprapaporn
opposite direction
Principal Positron Emitters
PET Radionuclides Physical T1/2PET Radionuclides Physical T1/2
C-11N-13
20 min10 minN-13
O-1510 min2 min
F-18 110 min
J Sriprapaporn
Steps for PET PET IMAGING
Imaging
Production of positron-emitting Rdnemitting Rdn.Labeling a selected compound with a
CYCLOTRONcompound with a positron-emitting Rdn.Administration into a
RADIOPHARM
Administration into a patient (IV, inhalation) Imaging the patient PET SCANNER
PATIENT
ag g t e pat e tReconstruction & display (Quantitation) COMPUTER
J Sriprapaporn
p y (Q )
PET CT I iCT PETPET/CT ImagingPET-CT ImagingCT PETImaging
Scout CTScout CCT low mA*PET scan-Non ACPET scan Non ACPET-ACPET(AC)-CT
J Sriprapaporn
PET(AC) CT
I d PET/CT SIntegrated PET/CT Scan
J Sriprapaporn
PET/CTPET/CT Scanners
Siriraj
J Sriprapaporn
FDG F 18 FDGFDG F-18 FDG
First synthesis by Ido et al (1974) at Brookhaven National Laboratory brain scan at HUP in 1976FDG= Fluorodeoxyglucose, glucose analogue, represents glucose metabolismrepresents glucose metabolism
FDG enters the cells using the same pathway as glucose (glucose transporter p y g (g pproteins) [R23: Mochizuki T, et al. JNM 2001]but is not used in glycolysis and ismetabolically trapped inside the cells aftermetabolically trapped inside the cells after phophorylation (FDG-6-phosphate). FDG is excreted in large quantities by kidney
J Sriprapaporn
FDG is excreted in large quantities by kidney unlike glucose.
FDG MetabolismFDG Metabolism
1Glycolysis
Glut
2
1G-6-P isomerase (Buck AK JNM 2004)
GlycolysisGlut
Enz1 = Hexokinase -- Phosphorylation
2
J Sriprapaporn
Enz1 = Hexokinase -- Phosphorylation
Enz2= Glucose-6-phosphatase
Tumor cells higher glycolytic rate than normal tissue.
Normal FDG PET/CT ImagingNormal FDG PET/CT Imaging
J Sriprapaporn
PET/CT SPECTPET/CT vs SPECT
Higher sensitivityHigher image qualityBetter anatomical localization with CTBetter anatomical localization with CT Whole-body imaging y g gMore accurate quantificationM t b li i i t ll l l lMetabolic imaging at cellular level
J Sriprapaporn
Mechanism of F-18 FDG UptakeMechanism of F 18 FDG Uptake
Malignant cells have increased gglucose utilization due to
O i f b lOver expression of membrane glucose transporter receptors, especially Glut-1 and Glut-3 on surface of tumor cells.Increased hexokinase activityIncreased hexokinase activityDecreased level of G-6-phosphatase
J Sriprapaporn
Clin Indications for PET/CT
DDx single pulmonary nodule, Grading tumorsStagingStagingMonitoring treatmentgDDx post therapeutic fibrosis & residual/recurrent tumorresidual/recurrent tumor
J Sriprapaporn
Table1: Medicare-approved l i di i fOncologic Indications for PET
*Special Medicare restrictions exist for these indications
J Sriprapaporn
p
Griffeth LK 2005
PET-CT Reimbursement in Thailand [26-11-07]
From 1 JAN 2008, 40,000 Baht/test for only 2Indications: Colon cancer & NSCLCIndications: Colon cancer & NSCLC
Colon cancer1. KPS > 70S 02. Suspected tumor recurrence due to rising CEA3. Negative or unclear CT or MRI of abdomen to
document recurrencedocument recurrence4. Abnormal CT or MRI supposed to be completely
resected. (for curative aim)If th fi t PET CT i di t d i ti th5. If the first PET-CT scan as indicated is negative, the PET study can be repeated at duration not less than 3 mos.
J Sriprapaporn
PET-CT Reimbursement in Thailand [26-11-07]
Non-small cell lung cancer 1. KPS > 702. Staging for curative aim
2.1 Clinical stage T2-3,N1-2 and Mo2.2 The patient had previous CT scan p pof chest adrenal and bone scan done.(no distant metas)
J Sriprapaporn
I i T h iImaging Techniques
Fasting for 4-6 hrs prior to PET/CT studyInject F-18 FDG 10-20 mCi IVInject F-18 FDG 10-20 mCi IVWait for 45-60 minutes to scanScanning time is about 30 minutes to complete PET/CT studies. SUVcomplete PET/CT studies. SUVmax
J Sriprapaporn
FDG PET-Single Pulmonary Nodule (SPN)
To identify pulmonary malignancy:y p y g ysens 82-100%, spec 67-100%, and accuracy 79-94%
Figure: SPN NSCLCFigure: SPN NSCLC
CT scan: a small nodule in the LULLULPET-FDG: intense accumulation
J Sriprapaporn
PET for N-Staging of NSCLC
CT: Left NSCLC w a pathologic AP window node (N2) (white), and a non-pathologic retrocaval-pretracheal contralateral mediastinal node (N3) (yellow). ( ) (y )PET-FDG images: increased tracer accumulation within both nodes, consistent with metastases. Thus PET is more sensitive than CT in detect small
J Sriprapaporn
Thus, PET is more sensitive than CT in detect small hypermetabolic LN metas.
FDG PETi i CMonitoring CMT Response
Baseline PET study is required!
Intense tumor uptake and nodal uptake of FDGp
Reduced metabolicReduced metabolic activity response to treatmenttreatment
J Sriprapaporn
Colorectal CA w Liver M P P RMetas.: Pre-Post Rx
Patient with colorectal metastases and previous left hemihepatectomyhemihepatectomy. A CT shows two hypodense nodules with contrast enhancement. B PET/CT fusion indicates a metastatic recurrent tumor beside a scar after operation. C CT after radiofrequencyC CT after radiofrequency ablation shows a large area without contrast enhancement(arrow). D PET/CT f i fD PET/CT fusion after radiofrequency ablationindicates complete ablation of the recurrent metastasis with a
J Sriprapaporn
photopenic lesion.
Colorectal CA w Liver Metas-Recurrence
A CT 3 month after radiofrequency ablation h f l lshows no sign of local recurrence.
B PET/CT 3 month after radiofrequency ablation d t t l l t t
J Sriprapaporn
demonstrates a local recurrent tumor.
Malignant Melanoma w Disseminated Metastases
J Sriprapaporn